1080 related articles for article (PubMed ID: 16563469)
21. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay.
Schäfer A; Weinberger S; Flierl U; Eigenthaler M; Störk S; Walter U; Ertl G; Bauersachs J
Thromb Haemost; 2008 Oct; 100(4):618-25. PubMed ID: 18841284
[TBL] [Abstract][Full Text] [Related]
22. Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits.
Wong PC; Crain EJ; Watson CA; Jiang X; Hua J; Bostwick JS; Ogletree ML; Schumacher WA; Rehfuss R
J Cardiovasc Pharmacol; 2007 May; 49(5):316-24. PubMed ID: 17513951
[TBL] [Abstract][Full Text] [Related]
23. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Sibbing D; Braun S; Morath T; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N
J Am Coll Cardiol; 2009 Mar; 53(10):849-56. PubMed ID: 19264241
[TBL] [Abstract][Full Text] [Related]
24. Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes.
Diehl P; Olivier C; Halscheid C; Helbing T; Bode C; Moser M
Basic Res Cardiol; 2010 May; 105(3):379-87. PubMed ID: 19943165
[TBL] [Abstract][Full Text] [Related]
25. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
Heart; 2010 Feb; 96(3):186-9. PubMed ID: 19687016
[TBL] [Abstract][Full Text] [Related]
26. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study.
Angiolillo DJ; Bernardo E; Palazuelos J; Desai B; Weisberg I; Alfonso F; Guzman LA; Hernández-Antolin R; Zenni MZ; Macaya C; Fernandez-Ortiz A; Bass TA
Thromb Haemost; 2008 Jan; 99(1):161-8. PubMed ID: 18217149
[TBL] [Abstract][Full Text] [Related]
27. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
[TBL] [Abstract][Full Text] [Related]
28. Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
Steinhubl S; Roe MT
Cardiovasc Drug Rev; 2007; 25(2):188-203. PubMed ID: 17614940
[TBL] [Abstract][Full Text] [Related]
29. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study.
Patti G; Nusca A; Mangiacapra F; Gatto L; D'Ambrosio A; Di Sciascio G
J Am Coll Cardiol; 2008 Sep; 52(14):1128-33. PubMed ID: 18804738
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis.
Pinto Slottow TL; Bonello L; Gavini R; Beauzile P; Sushinsky SJ; Scheinowitz M; Kaneshige K; Xue Z; Torguson R; Tantry U; Pichard AD; Satler LF; Suddath WO; Kent K; Gurbel P; Waksman R
Am J Cardiol; 2009 Aug; 104(4):525-30. PubMed ID: 19660606
[TBL] [Abstract][Full Text] [Related]
31. Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
Thromb Res; 2009 Nov; 124(5):588-91. PubMed ID: 19631365
[TBL] [Abstract][Full Text] [Related]
32. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Cavallari U; Trabetti E; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Pignatti PF; Macaya C
Thromb Res; 2005; 116(6):491-7. PubMed ID: 16181985
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
Storey RF; Husted S; Harrington RA; Heptinstall S; Wilcox RG; Peters G; Wickens M; Emanuelsson H; Gurbel P; Grande P; Cannon CP
J Am Coll Cardiol; 2007 Nov; 50(19):1852-6. PubMed ID: 17980251
[TBL] [Abstract][Full Text] [Related]
34. Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention.
Muller O; Hamilos M; Bartunek J; Ulrichts H; Mangiacapra F; Holz JB; Ntalianis A; Trana C; Dierickx K; Vercruysse K; De Bruyne B; Wijns W; Barbato E
Am J Cardiol; 2010 Feb; 105(3):333-8. PubMed ID: 20102944
[TBL] [Abstract][Full Text] [Related]
35. Comparison of a new P2Y12 receptor specific platelet aggregation test with other laboratory methods in stroke patients on clopidogrel monotherapy.
Bagoly Z; Sarkady F; Magyar T; Kappelmayer J; Pongrácz E; Csiba L; Muszbek L
PLoS One; 2013; 8(7):e69417. PubMed ID: 23844259
[TBL] [Abstract][Full Text] [Related]
36. Platelet function profiles in the elderly: results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity.
Capranzano P; Tamburino C; Capodanno D; Miccichè E; D'Urso L; Calvi V; Angiolillo DJ; Tamburino C
Thromb Haemost; 2011 Dec; 106(6):1149-57. PubMed ID: 22011914
[TBL] [Abstract][Full Text] [Related]
37. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug.
Labarthe B; Théroux P; Angioï M; Ghitescu M
J Am Coll Cardiol; 2005 Aug; 46(4):638-45. PubMed ID: 16098428
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up.
Marcucci R; Gori AM; Paniccia R; Giusti B; Valente S; Giglioli C; Buonamici P; Antoniucci D; Abbate R; Gensini GF
Circulation; 2009 Jan; 119(2):237-42. PubMed ID: 19118249
[TBL] [Abstract][Full Text] [Related]
39. P2Y12, a new platelet ADP receptor, target of clopidogrel.
Herbert JM; Savi P
Semin Vasc Med; 2003 May; 3(2):113-22. PubMed ID: 15199474
[TBL] [Abstract][Full Text] [Related]
40. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44.
Frelinger AL; Michelson AD; Wiviott SD; Trenk D; Neumann FJ; Miller DL; Jakubowski JA; Costigan TM; McCabe CH; Antman EM; Braunwald E
Thromb Haemost; 2011 Aug; 106(2):219-26. PubMed ID: 21713327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
